Sign in
Taking people in United StatesNo phase

Studying heart problems linked to cirrhosis of the liver in adults

Follows adults with cirrhosis to study cirrhotic cardiomyopathy, its risk factors and bile acids.

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Dallas and Nashville, United StatesSee the 2 sites
Trial code
Registry title
Prospective Investigation of Cirrhotic Cardiomyopathy in Humans
Status
Recruiting
People taking part
440 people, planned
Started
20 Jan 2026
Expected to end
30 Jun 2030
Type of study
Observational
Record updated
21 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with decompensated cirrhosis, meaning advanced liver scarring with complications. It studies heart problems linked to cirrhosis and the role of bile acids in the blood.

Age
18 years and older
Sex
All sexes
Disease stage
Decompensated cirrhosis: now or in the past, bleeding linked to high pressure in the liver's blood vessels, confusion caused by the liver (hepatic encephalopathy), or fluid in the belly (ascites). MELD 3.0 score ≥ 15 or Child Pugh Class B-C. Regular follow-up at the VUMC or UTSW liver clinics.
Earlier treatment
People who have had a TIPS procedure before cannot join.

Main reasons for not taking part

  • Heart disease now or in the past, such as blocked heart arteries, moderate or worse valve disease, cardiac amyloidosis, congenital heart disease, a pacemaker or implanted defibrillator
  • End-stage heart, kidney or lung disease, or pulmonary arterial hypertension
  • Acute on chronic liver failure grade 2-3, or advanced liver cancer (BCLC Stage C or D)
  • Ongoing alcohol use
  • Pregnancy

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Decompensated cirrhosis, defined as cirrhosis with current or prior occurrence of one or more of the following:; portal hypertension-related bleeding,; hepatic encephalopathy, and/or; clinical ascites
  • Model for End Stage Liver Disease version 3.0 (MELD 3.0) ≥ 15 or Child Pugh Class B-C
  • Age ≥ 18 years
  • Longitudinal follow up in either at Vanderbilt University Medical Center (VUMC) or University of Texas Southwestern (UTSW) hepatology clinics
  • Willing to adhere to study protocol
  • Able to provide written informed consent

Who cannot take part

  • Current or prior obstructive coronary artery disease, ≥ moderate valvular disease, > mild pericardial effusion, cardiac amyloidosis, congenital heart disease, pacemaker, or implantable cardioverter defibrillator
  • Prior TIPS
  • End-stage heart, kidney, or lung disease
  • Pulmonary Arterial Hypertension
  • Acute on Chronic Liver Failure (ACLF) grade 2-3 (i.e., ≥ 2 extrahepatic organ failures)
  • Advanced hepatocellular carcinoma (i.e., Barcelona Clinic Liver Cancer (BCLC) Stage C or D)
  • Ongoing alcohol use, by patient reporting or by phosphatidyl ethanol testing
  • Pregnancy

Where in United States

  • UT Southwestern Medical CenterDallas, United StatesContact: Lisa VanWagner,, MDTaking people
  • Vanderbilt University Medical CenterNashville, United StatesContact: Manhal IzzyTaking people

About the trial

What the trial wants to find out

Cirrhotic Cardiomyopathy (CCM) is a recognized complication of cirrhosis, but understudied despite recent retrospective data suggesting it may be common, affecting one in three patients with decompensated cirrhosis, and associated with significantly increased risk of death and adverse hepatic and cardiac events. Moreover, evidence from preclinical models and children suggest elevated bile acids in the blood may contribute to CCM, but data from adults with cirrhosis are scarce. Therefore, this study will be the first contemporary prospective multicenter investigation of CCM in adults with cirrhosis in the United States. The study will characterize risk factors for CCM, determine its impact on clinical outcomes, and investigate the contribution of circulating bile acids to disease development.

The group in the trial

  • Decompensated cirrhosis

    Patients with cirrhosis and current or prior occurrence of one or more of the following: • portal hypertension-related bleeding (a type of bleeding from the gut in patients with cirrhosis),• hepatic encephalopathy (i.e., alteration in mental status due to cirrhosis), and/or • clinical ascites (i.e., fluid build up in the abdomen). The cohort will then be analyzed based on the presence of cirrhotic cardiomyopathy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Prospective Investigation of Cirrhotic Cardiomyopathy in Humans
Plain-language title
Studying heart problems linked to cirrhosis of the liver in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
21 July 2026